Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically demonstrated BCG-unresponsive, carcinoma in situ (CIS)-containing high-risk non-muscle-invasive bladder cancer (NMIBC) defined as CIS with or without papillary component~* Participants must have CIS to be eligible.~* Predominant histologic component (\> 50%) must be urothelial (transitional cell) carcinoma~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~Exclusion Criteria:~* Sign of locally advanced disease or metastatic bladder cancer~* Urothelial cancer (UC) in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment~* Prior immuno-oncology therapy~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab monotherapy (Type: EXPERIMENTAL): None
- Nivolumab + BCG (Type: EXPERIMENTAL): None
- Nivolumab + BMS-986205 (Type: EXPERIMENTAL): None
- Nivolumab + BMS-986205 + BCG (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).